🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. CSL689

    CSL Behring GmbH

    Hemophilia A With Inhibitors

    phase 3 small molecule terminated

    1 trial

  2. CTX-009

    Compass Therapeutics

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  3. CTX001

    S.A.

    Beta-Thalassemia

    phase 3 mab active

    3 trials

  4. CTX001

    Vertex Pharmaceuticals (Australia) Pty.

    Beta-Thalassemia

    phase 3 mab active

    1 trial

  5. CYCLOPHOSPHAMIDE

    Pari Pharma GmbH

    The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT

    phase 3 small molecule active

    1 trial

  6. CYCLOPHOSPHAMIDE , -, PREDNISONE , PREDNISOLONE , VINCRISTINE, DOXORUBICIN , RITUXIMAB , Zilovertamab vedotin

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  7. CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE

    The George Institute

    Acute Lymphoblastic Leukaemia

    phase 3 small molecule active

    1 trial

  8. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  9. CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, POMALIDOMIDE, FLUDARABINE PHOSPHATE, DEXAMETHASONE, DEXAMETHASONE, DEXAMETHASONE SODIUM PHOSPHATE, CYCLOPHOSPHAMIDE, POMALIDOMIDE, DEXAMETHASONE, CARFILZOMIB, POMALIDOMIDE, DARATUMUMAB, GPRC5D-TARGETED CAR T, DEXAMETHASONE SODIUM PHOSPHATE, POMALIDOMIDE, TOCILIZUMAB

    Celgene Europe Limited

    Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  10. CYCLOPHOSPHAMIDE, Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion., DOXORUBICIN, DOCETAXEL

    Ningbo Cancer Hospital

    oestrogen-receptor (ER)-positive HER2-negative breast carcinoma

    phase 3 small molecule active

    1 trial

  11. CYCLOPHOSPHAMIDE, PACLITAXEL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, CAPECITABINE, EPIRUBICIN, IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE, CARBOPLATIN, INFLIXIMAB, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL, CYCLOPHOSPHAMIDE, PEMBROLIZUMAB, Datopotamab deruxtecan, Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, DOXORUBICIN

    AstraZeneca AB

    Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  12. CYTARABINE, CYTARABINE, Liposomal Annamycin, 0.9% Sodium Chloride Injection, USP/Ph. Eur./BP/JP

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  13. Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

    Sanofi-aventis Healthcare Pty Ltd

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  14. Cabozantinib

    Takeda

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  15. Cabozantinib Ipsen 60 mg film-coated tablets, XL092, XL092, XL092, BELZUTIFAN, Cabozantinib Ipsen 20 mg film-coated tablets, XL092

    Merck Sharp and Dohme

    Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. Cabozantinib, SELPERCATINIB, VANDETANIB, SELPERCATINIB, Cabozantinib, CABOZANTINIB

    Eli Lilly Co.

    RET-Mutant Medullary Thyroid Cancer

    phase 3 small molecule active

    1 trial

  17. Cadisegliatin 800 mg QD

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  18. Calcium carbonate

    Arrowhead Pharmaceuticals Ireland Limited

    Uterine Contraction

    phase 3 small molecule completed

    1 trial

  19. Caldolor

    CUMBERLAND PHARMACEUTICALS INC

    Pain

    phase 3 small molecule completed

    1 trial

  20. Caldolor

    CUMBERLAND PHARMACEUTICALS INC

    Fever

    phase 3 small molecule completed

    1 trial

  21. Caldolor

    CUMBERLAND PHARMACEUTICALS INC

    Burns

    phase 3 small molecule completed

    1 trial

  22. Calquence 100 mg hard capsules

    AstraZeneca AB

    Chronic lymphocytic leukemia

    phase 3 small molecule active

    1 trial

  23. Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  24. Camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 3 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources